Retinal Detachment Market

By Condition Type;

Rhegmatogenous Retinal Detachment, Tractional Retinal Detachment, and Exudative Retinal Detachment

By Treatment;

Photocoagulation (Laser Surgery), Cryopexy (Freezing), Pneumatic Retinopexy, Scleral Buckling, and Vitrectomy

By End User;

Hospitals & Clinics, Specialty Centers, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn157367251 Published Date: August, 2025

Retinal Detachment Market Overview

Retinal Detachment Market (USD Million)

Retinal Detachment Market was valued at USD 2,566.66 million in the year 2024. The size of this market is expected to increase to USD 4,579.83 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.6%.


Retinal Detachment Market

*Market size in USD million

CAGR 8.6 %


Study Period2025 - 2031
Base Year2024
CAGR (%)8.6 %
Market Size (2024)USD 2,566.66 Million
Market Size (2031)USD 4,579.83 Million
Market ConcentrationMedium
Report Pages315
2,566.66
2024
4,579.83
2031

Major Players

  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Alcon Inc. (a subsidiary of Novartis)
  • Genentech, Inc. (a subsidiary of Roche)
  • Bayer AG
  • Allergan plc (acquired by AbbVie Inc.)
  • Carl Zeiss Meditec AG
  • NIDEK Co., Ltd.
  • Bausch Health Companies Inc.
  • Topcon Corporation

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Retinal Detachment Market

Fragmented - Highly competitive market without dominant players


The Retinal Detachment Market advances on the back of larger at-risk cohorts, faster symptom recognition, and imaging-first care pathways. ~60–65% of urgent retina visits arise from photopsia or new floaters, with ~25–30% noting field loss. Streamlined triage reaches ~70% of symptomatic patients within 48 hours, enabling ~85–90% primary reattachment. Growing procedure volumes, higher diagnostic yield, and structured post-repair monitoring sustain market momentum.

Disease Burden & Care-Seeking
An under-diagnosis gap of ~35–40% persists, while ~50–55% of high-risk individuals lack symptom awareness. Among confirmed cases, ~45–50% report abrupt onset, accelerating specialist access. First-contact screening routes ~65% of referrals to retina services within 24–72 hours. Education initiatives boost self-reported early symptoms by ~20–25%, compressing delays to treatment.

Treatment Mix & Outcomes
PPV represents ~60–70% of primary repairs, with scleral buckle at ~15–25% and pneumatic retinopexy at ~10–15%. Single-operation success reaches ~85–90%, and re-intervention occurs in ~10–15%. Tamponade use appears in ~70–80% of PPV, while prophylactic laser is applied in ~30–35%. Enhanced recovery frameworks trim post-op complications by ~15–20%.

Technology & Innovation
Combining OCT with ultra-widefield imaging improves tear detection by ~25–30% compared with single-modality pathways. AI-driven triage cuts false negatives by ~20–30% and reduces reader time by ~35–40%. Small-gauge systems are used in ~75–80% of PPV procedures, supporting better comfort and throughput. Remote follow-up boosts adherence by ~30–35%, lowering recurrence by ~10–15%.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Condition Type
    2. Market Snapshot, By Treatment
    3. Market Snapshot, By End User
    4. Market Snapshot, By Region
  4. Retinal Detachment Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Technological Advancements in Retinal Detachment Treatments
        2. Increasing Incidence of Eye Disorders
      2. Restraints
        1. High Treatment Costs
        2. Limited Accessibility to Advanced Healthcare Facilities
      3. Opportunities
        1. Growing Awareness Programs and Campaigns
        2. Emerging Markets with Untapped Potential
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Retinal Detachment Market, By Condition Type, 2021 - 2031 (USD Million)
      1. Rhegmatogenous Retinal Detachment
      2. Tractional Retinal Detachment
      3. Exudative Retinal Detachmen
    2. Retinal Detachment Market, By Treatment, 2021 - 2031 (USD Million)
      1. Photocoagulation (Laser Surgery)
      2. Cryopexy (Freezing)
      3. Pneumatic Retinopexy
      4. Scleral Buckling
      5. Vitrectomy
    3. Retinal Detachment Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals And Clinics
      2. Specialty Centers
      3. Others
    4. Retinal Detachment Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Novartis AG
      2. Regeneron Pharmaceuticals, Inc.
      3. Alcon Inc. (a subsidiary of Novartis)
      4. Genentech, Inc. (a subsidiary of Roche)
      5. Bayer AG
      6. Allergan plc (acquired by AbbVie Inc.)
      7. Carl Zeiss Meditec AG
      8. NIDEK Co., Ltd.
      9. Bausch Health Companies Inc.
      10. Topcon Corporation
  7. Analyst Views
  8. Future Outlook of the Market